Document:

<PAGE>

                                                  [LOGO] EXIDE TECHNOLOGIES

                                                  Exide Technologies
                                                  Corporate Headquarters
                                                  210 Carnegie Center, Suite 500
                                                  Princeton, NJ 08540

                                                  609.627.7200 tel
                                                  609.627.7178 fax

                                                  www.exide.com

                                                                    Exhibit 10.1

December 18, 2002

Mr. Biagio N. Vignolo, Jr.
1 Old Chestnut Ridge Road
Montvale, NJ 07645

Dear Biagio:

It is with great pleasure that we extend an offer to you for the position of
Executive Vice President, Chief Financial Officer with Exide at a semi-monthly
salary of $17,708.33 (approximately $425,000 a year). This position will report
directly to the Chairman & CEO for Exide in our Corporate offices in Princeton,
NJ, subject to Board approval.

You will be eligible to participate in Exide's bonus plan with an annual target
bonus opportunity of 65% of your base salary. The amount can be more or less
depending upon the performance measures established and actual results of you
and the company.

As an integral part of the Exide team, you will be eligible to participate in
the Exide Restructuring Milestone Incentive Plan. The Restructuring Milestone
Incentive Plan is designed to reward key employees for achieving milestones and
objectives as we move towards approval of the company's plan of reorganization.
The details of the program will be provided at a later date, however 16.25% of
your hire date salary will be paid if certain previously agreed upon goals are
achieved on or before June 30, 2003. Another 16.25% of your hire date salary
will be paid upon the confirmation of the plan of reorganization.

You will receive $1,000 a month for car allowance.

Exide Technologies offers a comprehensive benefits program which includes:
medical, dental, life, accident, disability, and business travel insurance as
well as retirement savings plans, paid holidays and vacation. A summary of the
benefit plans is enclosed for your review. In the event you have any questions
regarding our benefits, please feel free to contact Tamika Hinton, Manager,
Human Resources at 678-566-9416.

As a key executive within the company, you will also be eligible for the income
protection program. This program provides income protection for two years of
base salary, target bonus, and actuarially calculated benefits for a change of
control as described in the plan document.

Consistent with Exide's commitment to provide a drug-free work environment for
all employees, this offer is contingent upon your successful completion of a
pre-placement drug test, as well as a satisfactory background check. Please
contact Tamika Hinton, to schedule an appointment for a drug screen at a
facility located closest to you. This offer is also contingent upon verification
of your Employment Eligibility (on Form I-9).

<PAGE>

Page 2, Exide Offer Letter - Biagio N. Vignolo, Jr.,
Executive Vice President, Chief Financial Officer, Exide

All who have met you are excited about working with you and look forward to
providing you with a challenging work environment. Speaking for myself, your
skills, competencies and work ethic would be an ideal fit for Exide, and equally
the culture would provide you with the environment and challenges you seek,
especially as we continually strive towards best in class.

Since this is a critical position for us, please confirm your acceptance of this
offer and the effective start date of January 1, 2003.

We are confident that your expertise will add meaningful value to our
organization and we look forward to your joining the Exide Team.

Sincerely,

Executive Vice President,
Global Human Resources
Janice M. Jones

Accepted:

/s/ BIAGIO N. VIGNOLO, JR.
--------------------------
    Biagio N. Vignolo, Jr.Supply and Distribution Agreement

 
Exhibit 10.20

 
SUPPLY AND DISTRIBUTION AGREEMENT

 

	 1.	  	 PARTIES 

 
This Agreement is made between 
 
VIRAGEN INTERNATIONAL LTD. having its principal address at 865 SW 78th Avenue, Suite 100, Plantation, FL 33324 and VIRAGEN (SCOTLAND) LTD. having its principal address at Pentland Science Park, Bush Loan, Peniculk, Midlothian
EH260 PPZ, UNITED KINGDOM, 
 
hereinafter referred
to as “the Company” and 
 
CJ
CORPORATION-PHARMACEUTICAL DIVISION, having its principal address at 212 Carnegie Center, Suite 302 – Princeton, NJ 08540
                                        
                                    . 
 
hereinafter referred to as “the Distributor”.

 

	 2.	  	 PURPOSE 

 
The purpose of this Agreement is to grant the Distributor the exclusive right to market, sell and distribute the Product within the
Territory as defined in Exhibit A and in accordance with the terms and conditions expressed herein. 
 

	 3.	  	 DEFINITIONS 

 
In this Agreement, each time the following terms are used with initial capitals, their meanings shall be as specified hereunder.

 

	  	 –	  	 “Affiliated Companies” shall mean, in relation to a given company, any company which, directly or indirectly, controls, is controlled by, or is under
common control with such company. 

 

	  	 –	  	 “Batch” and “Lot” shall mean a defined quantity of the Product which has been produced during a defined cycle of manufacture, and which is
identified by a unique production number. 

 

	  	 –	  	 “Contract Year” shall mean any period of 12 (twelve) consecutive calendar months following the Effective Date, as defined hereunder, or anniversary
thereof. 

 

	  	 –	  	 “Distribution Record” shall mean the record sheet detailing every shipment of the Product made by the Distributor to any of its customers including, but
not limited to, the customer’s name, address, batch number, number of bottles and date of shipment. 

 

1 of 13 

 

	  	 –	  	 “Effective Date” shall mean the first day of the month following the month during which the Distributor is granted the “Product License”,
hereinafter “PL”, as hereunder defined. 

 

	  	 –	  	 “Parties” shall mean the Company and the Distributor. 

 

	  	 –	  	 “Party” shall mean either the Company or the Distributor. 

 

	  	 –	  	 “PL” shall mean the Product License (or authorization under a physician prescription/named patient program) granted by the competent medical authorities
of the countries included in the Territory for allowing the sale and distribution of the Product in the Territory. 

 

	  	 –	  	 “Price” shall mean the price of the Product as described in Exhibit B. 

 

	  	 –	  	  “Product” shall mean MultiferonTM  as chemically described and with the specification given in Exhibit C as modified from time to time according to the provisions of Exhibit B. 

 

	  	 –	  	 “Recall Operation” shall mean the operation for recalling the Product if it is suspected or known to be defective. 

 

	 4.	  	 APPOINTMENTS 

 
The Company hereby appoints the Distributor as its exclusive Distributor for the Product in the Territory (as defined in Exhibit A) and
Distributor hereby accepts such appointment in accordance with the terms and conditions herein expressed. 
 

	 5.	  	 PRODUCT PURCHASE AND SUPPLY COMMITMENTS 

 

	 5.1	  	 Distributor and Company agree to the purchase and supply of the following U.S. Dollar purchase and sales of Product over the initial term of this Agreement per the
following Performance Schedule, subject to the terms and conditions herein expressed: 

 
Performance Schedule 
 

	  Period

	   	  Estimated Purchase in U.S. Dollars

	  First Year
	   	  $
	  360,750.00

	  Second Year
	   	  $
	  575,250.00

	  Third Year
	   	  $
	  690,300.00

	  Fourth Year
	   	  $
	  793,845.00

	  Five Year
	   	  $
	  912,600.00

	  TOTAL
	   	  $
	  3,332,745.00

 
SALES
FIGURES TO BE PROVIDED BY CJ CORPORATION ON OR BEFORE JANUARY 15, 2003. 
 
 

2 of 13 

 

	 5.2	  	 Distributor will initiate a 40 patient hepatitis C clinical evaluation if it is considered necessary or convenient for any of the countries in the territory.
Distributor will pay for all materials (including Product), costs and expenses incurred for clinical evaluations. The Company agrees to provide Distributor with a ten percent (10%) discount on the agreed pricing of the Product up until the
equivalent cost of the patients’ material (Product) has been absorbed after which the full price shall be paid by the Distributor. 

 

	 6.	  	 MEDICAL REGISTRATION 

 

	 6.1	  	 The Distributor shall take any and all necessary measures in order to obtain and maintain appropriate approvals from the regulatory authorities which shall include,
but not be limited to, a PL and authorization to distribute the Product in the Territory. All costs and expenses associated with obtaining regulatory approval and the necessary permits to sell the Product in the Territory shall be borne by the
Distributor (as described in Exhibit A). 

 

	 6.2	  	 If the PL is not obtained within eighteen (18) months from the date of the last signature to this Agreement in most of the countries within the Territory, Viragen
shall have the right to terminate the Agreement according to the conditions contained in Article 11 below. 

 

	 6.3	  	 The Distributor shall pay all regulatory and governmental registration fees, all the annual registration maintenance fees and other fees required for the sale of
the Product as promulgated by any local, regional or national governmental authority. 

 

	 6.4	  	 In the event the Company is not free to disclose to the Distributor any information required by the responsible regulatory or other authorities, the Company shall
be obliged to make such secret information available to the authorities on the Distributor’s behalf at its own cost and expense. 

 

	 6.5	  	 The Company shall receive two (2) copies of all registration certificates, documentation for reimbursement and any other data or documentation forthwith upon their
issuance. The Distributor specifically agrees to provide the Company with copies of all correspondence with the registration authorities as well as any and all government agencies. Each party shall furnish the other with information on any observed
unexpected side effects, injury, toxicity or sensitivity reaction associated with the clinical use, studies, investigations or tests of the Product in accordance with Exhibit D, which contains a sub-agreement.  

 

	 6.6	  	 Distributor will at its own cost register the Product in the territory 

 

3 of 13 

 

	 7.	  	 COMPETITION, REPORTS, FORECASTS, INFORMATION AND INVENTORY 

 

	 7.1	  	 Obligation Not to Compete 

 
The Company shall refrain from selling the Product in the Territory and shall not grant nor appoint any other person or entity as
Distributor of the Product in the Territory. 
 
The
Distributor shall not manufacture, sell or distribute any interferon or other products which compete with the Product. The Distributor may, however, continue its business activities with respect to such products as it sells or distributes on the
date of signing this agreement as reflected in Exhibit E. The Distributor may nominate a Sub-Distributor upon submission of a request for approval and a copy of the draft Sub-Distributor Agreement which shall be submitted to the Company for its
approval. No Sub-Distributor agreement shall be valid without the written approval of the Company. CJ to include name of products already in the market, as discussed.  
 
From the date of this agreement, Distributor shall not distribute, directly or indirectly, any products
containing the same active ingredients as the Product. 
 
The Distributor hereby warrants that it shall not seek customers for the Product outside the Territory, sell the Product outside the Territory, or establish any branch or maintain any distribution depot outside the Territory. The
Sub-Distributor Agreement shall require the Sub-Distributor to so warrant and the Distributor shall be accountable to the Company for enforcing this provision. 
 
The Distributor shall not have the right to produce the active ingredient of the Product. 
 

	 7.2	  	 Reports and Agreements 

 
The Distributor agrees to furnish the Company each calendar quarter, or at such intervals as agreed upon by the Company and the
Distributor, with a true and accurate report on all sales of the Product in the Territory, as specified herein. The Distributor agrees to also furnish the Company with copies of all agreements, brochures, pamphlets and documents which may relate to
the Product including those developed, produced or used by the Distributor in connection with the sale of the Product. The Distributor agrees not to use any such material without the Company’s prior written approval. Upon submission, the
Company agrees to respond promptly without any unnecessary delay and consent shall not be unreasonably withheld. 
 
At any time upon reasonable request of the Company, Distributor agrees to provide the Company with information, including but not limited
to, selling prices, market trends, competitive environment and competitor’s prices, technical or commercial information useful for the adaptation of the Product to market requirements. Distributor agrees to send to the Company a quarterly
report on market developments in the Territory and Distributor’s sales progress relating to the Product. 
 
At any time and upon reasonable request of the Company, Distributor shall permit the Company’s representative(s) to accompany
Distributor’s representative(s) on visits made to customers in order to have the Company better acquainted with the 
 

4 of 13 

 
specificity of
the market for the Product in the Territory. The Company agrees not to circumvent the Distributor during the term hereof and any renewal. 
 

	 7.3	  	 Forecasts 

 
Following PL approval, the Distributor shall submit to the Company each calendar quarter during each calendar year a rolling forecast for
the following 4 (four) quarters showing the planned purchase quantities of the Product. The Distributor shall place its firm orders for the Product for the following quarter with the rolling forecast. Before approval by the Company, the Distributor
shall submit each month a rolling forecast for the following twelve months connected to firm orders for the Product for the following quarter. 
 

	 7.4	  	 Information 

 
The Company shall provide the Distributor with all presently available data, information and documents necessary for the carrying out of
this Agreement, including technical documents and advertising material. 
 

	 7.5	  	 Inventory 

 
The Distributor shall buy and maintain, at his own cost, an inventory of the Product and see to it that the Product is kept in good
condition and that all reasonable precautions are taken to prevent its deterioration at its own cost, expense and liability. 
 

	 8.	  	 THE DISTRIBUTOR 

 

	 8.1	  	 Independency 

 

	 8.1.1	  	 For Its Own Account 

 
The Distributor shall buy and sell the Product in its own name and for its own account and act in all respects as an independent
contractor. The Distributor shall organize the distribution of the Product in such a manner as to most effectively promote the sale of the Product and maintain a level of product support necessary for the proper selling, marketing and distribution
of the Product. 
 

	 8.1.2	  	 Independent Contractor 

 
This Agreement does not designate the Distributor to be the agent, partner or legal representative of the Company for any purpose
whatsoever, and the business conducted by the Distributor pursuant to this Agreement with third parties shall be wholly at the Distributor’s own risk and account as an independent contractor. 
 
The Distributor is not granted any right or authority to
assume or create any obligation or responsibility, express or implied, on behalf of or in the name of the Company or to bind the Company in any manner whatsoever. 
 

5 of 13 

 

	 8.2	  	 Unfair Competition and Infringement of Rights 

 
The Distributor shall inform the Company of all acts of unfair competition and of all infringement of patents, trademark, trade names, or
similar rights of the Company which have come to its attention to the extent that the rights of the Company have been violated. If requested by the Company, the Distributor shall assist the Company at the Company’s expense in any action or
litigation involving such acts or infringements. 
 

	 8.3	  	 Distribution Records 

 
In order to enable the Company to comply with the requirements of the European Code of Good Manufacturing Practice (Volume IV of the Rules
Governing Medical Products in the European Community), the Distributor shall keep Distribution Records for each Batch of the Product sold to the customers. This information shall be made available to the Company in case of Recall Operation or upon
request, within two working days, by sending a fax, confirmed by a letter, to: 
 

	  ViraNative AB
	  	  Viragen (Scotland) LTD.

	  Tvistevagen 48
	  	  Pentland Science Park

	  S-907 36 Umeä
	  	  Bush Loan, Peniculk

	  Sweden
	  	  Midlothian EH260 PPZ

	  	  	  United Kingdom

	  Tel no: 46-90-172250
	  	  Tel no: 44-131-445-6268

	  Fax no: 46-90-193736
	  	  Fax no: 44-131-445-6269

 

	 9.	  	 CONDITIONS OF SALE 

 

	 9.1	  	 Purchase Orders 

 
The Distributor shall present all orders for the Product to be purchased under this Agreement to the Company together with adequate
delivery instructions and pre-payment. Orders presented by the Distributor shall bind the Company only after written confirmation of acceptance thereof by the Company. 
 

	 9.2	  	 Price Guidelines 

 

	 9.2.1	  	 Price and Conditions 

 
The Distributor shall purchase the Product at prices and on conditions set forth by the Company from time to time in Exhibit B.
Notwithstanding the above, the Company shall be entitled to change any Product Price at any time subject to giving Distributor six (6) months prior written notice. 
 

6 of 13 

 

	 9.2.2	  	 Payment Terms 

 
The Distributor shall pay the Company for the Product supplied according to payment terms as set forth in Exhibit B. 
 

	 9.3	  	 Advertising and Promotion 

 

	 9.3.1	  	 Best Efforts 

 
The Distributor shall use its best efforts and diligence in promoting and initiating effectively the sales of the Product throughout the
whole of its Territory. 
 

	 9.3.2	  	 Advertising and Promotional Activities 

 
The Distributor shall ensure the advertising and the promotion of the Product and, to a reasonable extent, the participation in
conventions, trade shows and exhibitions held in the Territory. The costs of advertising and promotion are to be borne by the Distributor. All advertising and promotional copy shall be submitted to the Company for its written approval prior to
release. 
 

	 9.3.3	  	 Conformity with Applicable Laws 

 

	 9.3.4.	  	 The Distributor shall be responsible for any advertising and promotional material for the Product and for their conformity with applicable laws and regulations.

 

	 9.3.5	  	 Thirty (30) days before the first delivery takes place, Distributor shall provide the Company with the art works of: 

 

	  	 -	  	 the carton 

	  	 -	  	 the labels for the Product and the cardboard box per the models communicated by the Company to the Distributor, and the leaflets to be packed with the Product

 

	   	  	 all of which shall be approved by the Company. 

 

	 9.3.6	  	 Before approval, the Company will deliver the Product in ampoules of 3 and 6 MIU, labeled with English text indicating batch numbers and expiration date, packed in
plastic trays, each containing five ampoules. 

 

	 9.3.7	  	 Distributor shall be responsible for delivering copy of any text in local language that may be required under law, rule or regulation. 

 

	 10.	  	 GENERAL PROVISIONS 

 

	 10.1	  	 Trade Secrets 

 
The Distributor shall not, even after the expiration of this Agreement, use or communicate to any third party any trade secrets which the
Distributor has come to know in one way or another through its work for the Company. The obligation shall 
 

7 of 13 

 
cease at the
end of a period of (five) 5 years from the date of the termination or expiration of this Agreement; however, the obligation shall not cease for any reason prior to the end of the first (ten) 10 years after the signing of the Agreement. 
 
The Distributor assumes the responsibility, liability and
obligations that its employees and any Sub-Distributor and its employees shall preserve the secrecy of trade secrets with respect to third parties. 
 

	 10.2	  	 Trademarks 

 
Trademarks, Tradenames and Copyrights used by the Distributor for the Product shall be the property of the Company, and the Distributor
agrees to use only such Trademarks, Tradenames and Copyrights as indicated and approved in writing by the Company. It is agreed that the Company’s registered trademark of the Product, MultiferonTM may be used in the CJ Territory, provided a registration of these trademarks will be obtainable and maintained. 
 
The Distributor shall not, without the Company’s prior
written consent, use the Company’s corporate name, telegraphic address, graphic or other trademarks, whether during the maintenance of or after the termination of this Agreement. 
 
The Distributor shall not register or attempt to register for any purpose any trade-mark, tradename,
copyright, name, title or expression of the Company as used on the Product or any other trademark or any tradename which is similar thereto. 
 
Electronic emails may be considered adequate consent if originated at the Company’s premises. 
 
The Company shall not be liable to compensate the Distributor
for any claims, expenses, costs, losses or damages the Distributor may suffer as a result of the infringement of any third party intellectual property rights in connection with the transactions contemplated hereunder. 
 

	 10.3	  	 Assignment 

 
The Company shall have the right to assign this Agreement, upon written notice to Distributor but without the prior consent of
Distributor, to: 
 

	  	 a)	  	 any of its Affiliated Companies; or 

 

	  	 b)	  	 its successors in interest as a result of a statutory merger or consolidation; or 

 

	  	 c)	  	 a company acquiring all or substantially all of the Company’s business and assets including the part concerned by this Agreement. 

 
The Company reserves the right to terminate this Agreement
whenever the control of the Distributor’s company passes over to another party than the party controlling it at the time of signature of this present Agreement. Exhibit F lists the current stockholders of the Distributor and its affiliates.

 

	 10.4	  	 Force Majeure 

 
If due performance of this Agreement by either party is affected in whole or in part by reason of any event, omission, accident, general
shortage of commodities, legal 
 

8 of 13 

 
circumstances
or other matter beyond the reasonable control of such party, it shall give prompt notice thereof to the other party and shall be under no liability for any loss, damage, injury or expense suffered by the other party for this reason. Both parties
shall use all reasonable efforts to avoid or overcome the causes affecting performance and the party whose performance is affected by such force majeure shall fulfill all outstanding obligations as soon as possible. 
 

	 10.5	  	 Warranties and Liability 

 

	 10.5.1	  	 The Company warrants to the Distributor that the Product delivered hereunder shall comply with the specification set forth in the Product License and consistent
with Exhibit C. 

 

	  	 a)	  	 If the parties agree that a certain lot of the Product supplied hereunder fails to meet said specification or is otherwise defective or if such lot is recognized as
defective by an independent laboratory as provided for hereafter in this section, and unless otherwise mutually agreed upon, the Distributor shall send such lot back to the Company and the Company shall replace it at its own expense, including the
freight back, with a new lot of the Product conforming with said specification. The Distributor shall have no other remedies against the Company for defects in the Product. 

 

	  	 b)	  	 If the parties fail to agree that a certain lot of the Product supplied hereunder meets said specification, Distributor may request an expert appraisal by an
independent laboratory, not associated with any of the parties hereto, to determine whether the Product complies with said specification. Should the Company disagree with regard to the choice of laboratory, the Company has the right to request that
the laboratory is appointed by the International Chamber of Commerce provided that the Company informs the Distributor within two weeks after having been informed by the Distributor about its choice of laboratory, that the Company requests that the
appraisal shall be carried out by a laboratory appointed by the Chamber. The report of the laboratory shall be conclusive and binding on the parties hereto. All expenses related to such appraisal shall be borne by the party, whose opinion of which
has been found not to be correct. 

 

	  	   	  	 No other warranties, expressed or implied, including, without limitation, merchantability or fitness for a particular purpose, are made or will be deemed to have
been made by the Company regarding the Products, except to the extent expressly stated herein. Neither the Distributor, nor any of its employees, agents or representatives is authorized to give any warranties or make any representations on behalf of
the Company. In no event shall the Company be held liable for any lost profits or any other incidental or consequential damages in connection with any claims arising out of or related to any products supplied by the Company to the Distributor.

 

	 10.5.2	  	 The Distributor shall indemnify and hold the Company harmless from and against any and all liability, damage, loss, cost or expense arising out of or resulting from
any claims made or suits brought against the Company or the Distributor, which arise out 

 
 

9 of 13 

 
 

	   	  	 of or result from the Distributor’s negligent act or omission in the marketing, selling or distribution of the Product. 

 

	 10.5.3	  	 The Distributor has, and shall at all times during the term of this Agreement and for a period of two years thereafter, have full insurance coverage with reputable
and sound insurance covering all and any risks, including (without limitation) any liabilities to third parties and the public (including without limitation product liability). The Company will have the right to review the insurance policies in
order to make sure the Distributor’s insurance coverage is sufficient. 

 

	 10.5.4	  	 The Company represents that it will add the Distributor as a Named Insured on its current International Liability Insurance Policy held with MedMarc Casualty and
Insurance Company under Policy Number 00FL020010 within 30 days from the date of execution of this agreement. 

 

	 10.5.5	  	 Compliance with Applicable Laws 

 
The Distributor agrees that it will, on its own comply with all laws, statutes and ordinance in the Territory relating to the import and
sale of the Product and agrees to indemnify and hold the Company harmless in the event that any claim is made against it by reason of the Distributor’s failure to so comply. In particular, the Distributor agrees to comply with all safety laws
and regulations in the Territory relating to the Product and the Company agrees to provide all necessary information and assistance to the Distributor to enable it to so comply. 
 

	 10.6	  	 Taxes 

 
The Distributor shall pay all excise or sales taxes that may be required to be paid by the Company or the Distributor by any statute,
ordinance or regulation of any taxation authority. In the event that the Company is required to or does pay any of such taxes, the Distributor, upon being informed of such payment, shall at once repay the amount thereof to the Company. The
Distributor, unless prohibited by any such statute, ordinance or regulation, shall have the right to require any dealer or Sub-Distributor handling such goods to pay any such excise or sales taxes on the goods so handled by him. 
 

	 11.	  	 DURATION AND TERMINATION 

 

	 11.1	  	 Duration 

 
This Agreement shall have immediate force and effect and shall remain in effect until the completion of the Fifth Period described in
Paragraph 5.1 of this Agreement and shall continue thereafter for an additional three (3) year term and continue thereafter for two automatic three (3) year terms unless and until terminated by either party giving to the other six (6) months notice
in writing prior to the end of the Initial Term or any Subsequent Term. 
 

10 of 13 

 

	 11.2	  	 Termination 

 

	 11.2.1	  	 Failure to Fulfill Obligations or to Obtain or Maintain PL 

 
This Agreement may be terminated with three (3) months written notice forthwith by either party if the other party fails to fulfill any of
its obligations under this Agreement and such default is not remedied within thirty (30) days of the date on which a written notice thereof has been dispatched to the defaulting party or if the Distributor fails to obtain or maintain the PL as set
forth in Article 6, Medical Registration. 
 

	 11.2.2	  	 Termination for Bankruptcy or Insolvency 

 
This Agreement may be terminated immediately in the event that either party is declared insolvent, is adjudged bankrupt or files a
petition for bankruptcy or re-organization under any bankruptcy law, is expropriated or sequestrated or submits or has to submit to any other administrative or judicial measures of control. 
 
Insolvency is defined to mean the inability to pay debts, as
they become due and the excess of liabilities over assets. 
 

	 11.2.3	  	 Termination for Loss of License to Sell Product 

 
The Company shall have a right to terminate this Agreement with immediate effect should the Company’s license to sell the Product be
withdrawn. 
 

	 11.3	  	 Effect of Termination 

 
On the termination of this agreement, the Distributor shall return, without delay, all registration and permission documents to the
Company together with all formulas, manufacturing procedures and other confidential documentation which the Distributor has obtained from the Company. The Distributor agrees that it shall not make any further use of this documentation. The Company
shall have the option to repurchase any paid unsold Product at prices paid by the Distributor to the Company. 
 

	 11.4	  	 Notice of Termination 

 
Provided that notice of termination has been dispatched by registered letter, the notice shall be considered to have been received by the
addressee four days after the letter was so dispatched. 
 

	 11.5	  	 Exclusive and Non-Exclusive Distribution Rights 

 
In the event Distributor fails to achieve seventy percent (70%) of the sales figures set forth under “Performance Standards” in
paragraph 5.1, then the exclusive distribution rights as set forth herein may be cancelled in the Company’s sole discretion. If the exclusive rights are so cancelled, then Distributor shall have non-exclusive distribution rights within the
Territory. Distributor shall remain the exclusive distributor within the Territory during the term of this agreement and any renewal 
 

11 of 13 

 
thereof in the
event Distributor has generated one-half or more of the sales figures set forth under Performance Standards in paragraph 5.1. This provision shall not apply during the first 18 months of the term of this Agreement and sales shall be calculated on a
12-month basis thereafter. 
 

	 11.6	  	 Termination Compensation 

 
Neither party hereto shall be liable to the other for any termination compensation whether based on goodwill, loss of income or otherwise.

 

	 12.	  	 FINAL PROVISIONS 

 

	 12.1	  	 Governing Law 

 
This Agreement shall be governed by the laws of the U.K. 
 

	 12.2	  	 Language 

 
The English text of this Agreement shall prevail. 
 

	 12.3	  	 Arbitration 

 
Any dispute in connection with this agreement shall be finally settled by arbitration in accordance with the Rules of the Arbitration Act
of the International Chamber of Commerce and the settlement will take place in Edinburgh, Scotland and be conducted in the English language. 
 

	 12.4	  	 Modifications 

 
All modifications and amendments to this Agreement shall be in writing. 
 

	 12.5.	  	 Notices and Communications 

 
All notices in connection with this Agreement shall be in writing and be in the English language, as shall all other written
communications and correspondence, and may be given by personal delivery, prepaid registered airmail letter, telecopier, or telegram addressed to the Party required or entitled to receive the same at its address or telefax number set out below, or
to such other address or telefax number as such Party shall have designated by like notice to the other Party. Notice of termination of this Agreement if given by telecopier or telegram shall be confirmed by prepaid registered airmail letter dated
and posted within 24 hours. The effective date of any notice if served by personal delivery, telecopier, or telegram shall be deemed the first business day in the city of destination following the dispatch and if given by prepaid registered airmail
letter only, it shall be deemed served seven days after the date of posting. 
 

	 12.6	  	 Exhibits 

 
All Exhibits attached hereto shall be made a part of this Agreement. 
 

12 of 13 

 

	 12.7	  	 No Waiver 

 
The omission by either Party to exercise any right hereunder shall not constitute a waiver thereof and shall not prevent the subsequent
enforcement of that right and shall not be deemed to be a waiver of any subsequent right. 
 

	 12.8	  	 Survival of Provisions 

 
The provisions of this Agreement shall survive its termination for so long as may be necessary to give efficacy thereto. 
 

	 12.9	  	 Entire Agreement 

 
This Agreement, which includes the Exhibits attached hereto, contains the entire understanding and supersedes all prior agreements of the
parties with respect to the transactions contemplated hereby. There are no agreements, promises, warranties, covenants or understandings other than those expressly set forth herein. 
 

	 12.10	  	 Invalidity 

 
Any provision of this Agreement that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the
extent of such invalidity or unenforceability without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction. 
 
IN WITNESS WHEREOF the parties hereto have hereunto set their hands the day and year indicated below. 
 

	  VIRAGEN INTERNATIONAL LTD.
	  	  	  	  CJ Pharma

	
	  By:
	  	  /s/ Gerald Smith, CEO

	  	  	  	  By:
	  	  /s/ Jong H Kim, Director

	  (Name and Title)
	  	  	  	  (Name and Title)

	
	  Print:
	  	  Gerald
Smith             Date: 11/5/02
	  	  	  	  Print:
	  	  Jong H
Kim             Date: 10/18/02

 
VIRAGEN (SCOTLAND) LTD. 
 

	
	  By:
	  	  /s/ Gerald Smith, Director

	  (Name and Title)

	
	  Print:
	  	  Gerald
Smith             Date 11/5/02

 

13 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]